A Study With NLY01 in Subjects With Type 2 Diabetes
NCT04159766 on ClinicalTrials.gov · last registry update 2021-03-02
A small phase 2 — 20 participants, against a typical 110. The sponsor logged completion for 4 December 2020. Primary outcome, as filed: Number of participants with Treatment Emergent Adverse Events. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Neuraly, Inc.
- Sponsor type
- Industry
- Enrollment
- 20
- Started
- 2019-10-16
- Primary completion
- 2020-12-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of participants with Treatment Emergent Adverse Events
Conditions studied
Type2 Diabetes · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.